Related references
Note: Only part of the references are listed.Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial
Joris B. W. Elbers et al.
RADIOTHERAPY AND ONCOLOGY (2020)
STAT1 inhibits T-cell exhaustion and myeloid derived suppressor cell accumulation to promote antitumor immune responses in head and neck squamous cell carcinoma
Nathan Ryan et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma
Aly-Khan A. Lalani et al.
EUROPEAN UROLOGY ONCOLOGY (2020)
Head and Neck Cancer
Laura Q. M. Chow
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer
Taylor T. Chrisikos et al.
MOLECULAR IMMUNOLOGY (2019)
Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates
Luca Cassetta et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort
Neil H. Segal et al.
EUROPEAN JOURNAL OF CANCER (2019)
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Michael Platten et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors
Arielle Elkrief et al.
ONCOIMMUNOLOGY (2019)
Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
Jacob H. Rasmussen et al.
BRITISH JOURNAL OF CANCER (2019)
The Intersection between Tumor Angiogenesis and Immune Suppression
Osama E. Rahma et al.
CLINICAL CANCER RESEARCH (2019)
Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Danny Rischin et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer
Sha Zhao et al.
LUNG CANCER (2019)
CANCER Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response
Rajarsi Mandal et al.
SCIENCE (2019)
Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer
Jill M. Brooks et al.
CLINICAL CANCER RESEARCH (2019)
Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade
Andrew Georgiadis et al.
CLINICAL CANCER RESEARCH (2019)
APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma
Daniel L. Faden et al.
ORAL ONCOLOGY (2019)
Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma
Lei Wu et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy
Y. -P. Chen et al.
ANNALS OF ONCOLOGY (2019)
Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
Houda Bahig et al.
BMC CANCER (2019)
JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer
Yao Yu et al.
FUTURE ONCOLOGY (2019)
Human papillomavirus and the landscape of secondary genetic alterations in oral cancers
Maura L. Gillison et al.
GENOME RESEARCH (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC The Phase 2 CONDOR Randomized Clinical Trial
Lillian L. Siu et al.
JAMA ONCOLOGY (2019)
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance
Jinfang Zhang et al.
NATURE (2018)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models
Robert D. Leone et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients
Zhuqing Liu et al.
CLINICAL CANCER RESEARCH (2018)
Specific blockade CD73 alters the exhausted phenotype of T cells in head and neck squamous cell carcinoma
Wei-Wei Deng et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments
Kevin C. Barry et al.
NATURE MEDICINE (2018)
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L. Ferris et al.
ORAL ONCOLOGY (2018)
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Limo Chen et al.
CANCER DISCOVERY (2018)
Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
Maarten Versteven et al.
FRONTIERS IN IMMUNOLOGY (2018)
IKZF1 Enhances Immune Infiltrate Recruitment in Solid Tumors and Susceptibility to Immunotherapy
James C. Chen et al.
CELL SYSTEMS (2018)
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
Rikke B. Holmgaard et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial
A. D. Colevas et al.
ANNALS OF ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Increased Tim-3+ T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients
Ryo Kato et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Human Papilloma Virus Specific Immunogenicity and Dysfunction of CD8+ T Cells in Head and Neck Cancer
Krishna et al.
CANCER RESEARCH (2018)
Crucial role of CD69 in anti-tumor immunity through regulating the exhaustion of tumor-infiltrating T cells
Yukiyoshi Mita et al.
INTERNATIONAL IMMUNOLOGY (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
K. G. Paulson et al.
NATURE COMMUNICATIONS (2018)
Overcoming Acquired PD-1/PD-L1 Resistance with CD38 Blockade
Deepak Mittal et al.
CANCER DISCOVERY (2018)
Treatment-naive HPV plus head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy
Steven F. Gameiro et al.
ONCOIMMUNOLOGY (2018)
The metabolite BH4 controls T cell proliferation in autoimmunity and cancer
Shane J. F. Cronin et al.
NATURE (2018)
Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration
Ayman Oweida et al.
CLINICAL CANCER RESEARCH (2018)
Frameshift events predict anti-PD-1/L1 response in head and neck cancer
Glenn J. Hanna et al.
JCI INSIGHT (2018)
Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide
Marco C. Merlano et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2018)
Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals
Gulidanna Shayan et al.
CLINICAL CANCER RESEARCH (2018)
Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma
Lei Chen et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2018)
Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages
Hideyuki Takahashi et al.
ONCOTARGET (2017)
Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer
Gulidanna Shayan et al.
ONCOIMMUNOLOGY (2017)
LAG3 (CD223) as a cancer immunotherapy target
Lawrence P. Andrews et al.
IMMUNOLOGICAL REVIEWS (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
Chiun Hsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Joshua Bauml et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma
Daniel L. Faden et al.
ORAL ONCOLOGY (2017)
Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients
Richard Linedale et al.
PLOS ONE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Scott Gettinger et al.
CANCER DISCOVERY (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment
Melanie Mediavilla-Varela et al.
NEOPLASIA (2017)
Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study
Salvinia Mletzko et al.
ONCOIMMUNOLOGY (2017)
Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment
Susanne M. Steggerda et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion
Lee A. Albacker et al.
PLOS ONE (2017)
The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade
J. -P. Foy et al.
ANNALS OF ONCOLOGY (2017)
Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma
Lei Wu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma
Maria Vassilakopoulou et al.
CLINICAL CANCER RESEARCH (2016)
An adaptive immune response driven by mature, antigen-experienced T and B cells within the microenvironment of oral squamous cell carcinoma
Hongzhi Quan et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment
Koichi Sakakura et al.
LABORATORY INVESTIGATION (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells
Fernando Concha-Benavente et al.
ORAL ONCOLOGY (2016)
Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma
Yuta Kondo et al.
ORAL ONCOLOGY (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity
Melanie Straub et al.
ONCOTARGET (2016)
Microsatellite alteration in head and neck squamous cell carcinoma patients from a betel quid-prevalent region
Jin-Ching Lin et al.
SCIENTIFIC REPORTS (2016)
Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma
Hae Su Kim et al.
CANCER RESEARCH AND TREATMENT (2016)
The PD1:PD-L1/2 Pathway from Discovery to Clinical implementation
Kankana Bardhan et al.
FRONTIERS IN IMMUNOLOGY (2016)
Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx Analysis System
Brett Wallden et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The head and neck cancer immune landscape and its immunotherapeutic implications
Rajarsi Mandal et al.
JCI INSIGHT (2016)
EBV Oncogene N-LMP1 Induces CD4 T Cell-Mediated Angiogenic Blockade in the Murine Tumor Model
Tzong-Shoon Wu et al.
JOURNAL OF IMMUNOLOGY (2015)
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma
Patcharee Ritprajak et al.
ORAL ONCOLOGY (2015)
Therapeutic Insights from Genomic Studies of Head and Neck Squamous Cell Carcinomas
Peter S. Hammerman et al.
CANCER DISCOVERY (2015)
Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors
Mark Ayers et al.
Journal for ImmunoTherapy of Cancer (2015)
Risk of Cancer in Patients with Iron Deficiency Anemia: A Nationwide Population-Based Study
Ning Hung et al.
PLOS ONE (2015)
A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
Ivraym B. Barsoum et al.
CANCER RESEARCH (2014)
Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways
Patrick L. Raber et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Targeting Cancer-Derived Adenosine: New Therapeutic Approaches
Arabella Young et al.
CANCER DISCOVERY (2014)
PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer
Cecile Badoual et al.
CANCER RESEARCH (2013)
Iron in Infection and Immunity
James E. Cassat et al.
CELL HOST & MICROBE (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes
Monica Bernal et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes
Michael S. Leibowitz et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity
Sebastian F. M. Haeusler et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
IMMUNOREGULATORY PROPERTIES OF CD44+CANCER STEM-LIKE CELLS IN SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Kazuaki Chikamatsu et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2011)
Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas
Klaus Laimer et al.
ORAL ONCOLOGY (2011)
Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: Bases for improved immunotherapy
Debora Martorelli et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology
Fabio Malavasi et al.
PHYSIOLOGICAL REVIEWS (2008)
HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker
Takeshi Ogino et al.
CANCER RESEARCH (2006)
A2A adenosine receptor protects tumors from antitumor T cells
Akio Ohta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Microsatellite instability and methylation of the DNA mismatch repair genes in head and neck cancer
S. Demokan et al.
ANNALS OF ONCOLOGY (2006)
Transforming growth factor-β1 immobilises dendritic cells within skin tumours and facilitates tumour escape from the immune system
F Weber et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Share Paper
